GC
HBIO icon

Guggenheim Capital’s Harvard Bioscience HBIO Stock Holding History

Guggenheim Capital’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1,245
Closed -$57K – 3045
2014
Q2 		$57K Sell
1,245
-552
-31% -$23.2K ﹤0.01% 3067
2014
Q1 		$85K Buy
1,797
+298
+20% +$13.6K ﹤0.01% 3053
2013
Q4 		$71K Sell
1,499
-321
-18% -$14K ﹤0.01% 3020
2013
Q3 		$72K Buy
1,820
+125
+7% +$4.92K ﹤0.01% 2897
2013
Q2 		$61K Buy
+1,695
New +$64.9K ﹤0.01% 2886

Other funds holding HBIO

GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HSA
Hussman Strategic Advisors Ellicott City, Maryland $463M AUM 16% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Guggenheim Capital's HBIO Position: Q3 2014 in Review

Guggenheim Capital sold out of Harvard Bioscience (HBIO) in Q3 2014, closing a stake of 1,245 shares — an estimated $57K sold.

Guggenheim Capital first reported a position in HBIO in Q2 2013 and held it in 5 quarters. The position peaked at $85K in Q1 2014. 72 funds tracked by Wall St. Rank hold HBIO as of Q3 2014.

  • Guggenheim Capital reported no remaining Harvard Bioscience position as of Q3 2014 after selling out during the quarter.
  • Guggenheim Capital sold 1,245 Harvard Bioscience shares in Q3 2014, an estimated $57K.
  • Guggenheim Capital first reported a position in Harvard Bioscience in Q2 2013 and held it in 5 quarters.
  • Guggenheim Capital's Harvard Bioscience position peaked at $85K in Q1 2014.
  • 72 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2014.

Based on Guggenheim Capital's 13F filing for Q3 2014, filed 14 Nov 2014.